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1. Introduction   
Contrast-induced nephropathy (CIN) is defined as acute deterioration of renal function after 
intravascular administration of iodinated contrast agents, in the absence of other causes. 
Laboratory diagnosis is expressed as an increase in serum creatinine levels of 0.5 mg/dL (or 
44 μmol/L) or a 25% or greater relative increase from baseline 48-72 hours after a diagnostic 
or interventional procedure, even if the clinical significance of this definition in the absence 
of pre-existing renal failure is questionable (Thomsen & Morcos, 2006). 
The Acute Kidney Injury (AKI) Network was estabilished in 2007 to study the improvement 
of outcomes associated with various forms of acute renal failure; recently, it has expressed 
the hope that the diagnostic criteria for all cases of acute kidney injury are standardized in 
sudden reduction (within 48 hours) of renal function with a serum creatinine increase ≥ 0.3 
mg/dL or a 50% or greater increase from baseline, or after onset of oligoanuria (urinary 
output < 0.5 mL/kg/hour for 6 hours) (Mehta et al., 2007).  
However, there is no consensus in bringing CIN parameters in AKI criteria, because contrast 
medium damage usually causes a serum creatinine peak on the third-fifth day after contrast 
medium exposure, and rarely occurs with oligoanuria, except in patients with advanced 
impairment of renal function (Detrenis et al., 2007a). Nevertheless, recent literature uses the 
term “radiocontrast-induced acute kidney injury” (RCI-AKI) rather than CIN, although the 
clinical implications of different definitions have never been tested on a large scale 
(Goldfarb et al., 2009). 
2. Epidemiology 
RCI-AKI is today the third nosographic entity related to hospital-acquired acute renal 
failure, after organ hypoperfusion and nephrotoxic drugs (eg, nonsteroidal anti-
inflammatory drugs) (Nash et al, 2002). RCI-AKI incidence is significantly greater in the 
case of intra-arterial (from 10-20% for moderate to 25-70% for high-risk patients; 0.15-
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The probability of renal replacement therapy is closely related to individual patient 
comorbidities, but it is reasonable to assume that it varies from less than 1% of all patients 
undergoing percutaneous coronary intervention to 10%of those with pre-existing alteration 
in renal function parameters who have RCI-AKI after coronary angiography (Meschi et al., 
2006). In other words, the probability of RCI-AKI requiring dialysis increases from 0.04 to 
48% if measured glomerular filtration rate is reduced from 50 to 10 mL/min; on the other 
hand, 13-50% of subjects undergoing dialysis after RCI-AKI tends to prolong renal 
replacement therapy definitively (Toprak, 2007).    
As in general for nephropatic patients, even for those affected by RCI-AKI the incidence of 
associated cardiovascular events or major adverse cardiac effects was assessed: a study on 
16.000 hospitalized subjects who underwent coronary angiography (Levy et al., 1996) shows 
that those with RCI-AKI develop a risk for complications and death 5-fold higher than in 
controls, even after data correction for any existing comorbidities. Even for the majority of 
cases, with benign clinical course (pre-existing serum creatinine values restoration in 1-3 
weeks, no symptoms or dialysis), there was a significant increase in 1- and 5-years mortality 
(Rihal et al., 2002). This evidence is greater for cases with unfavourable renal prognosis 
requiring temporary renal replacement therapy (McCullough et al., 1997).  
Consequently, even if the pathophysiological relationship between contrast nephropathy, 
morbidity and mortality it is not clear, RCI-AKI is today definitely considered an 
independent predictor for long term mortality. It is possible to hypothesize that the 
pathogenic process underlying RCI-AKI may interfere with pro-atherogenic mechanisms of 
cardiovascular disease, although there are no definitive studies on this issue (Detrenis et al., 
2005). 
3. Risk markers for contrast nephropathy 
The pathogenetic events underlying RCI-AKI are still not completely understood and the 
identification of “risk factors” for disease is difficult, because the term usually refers to a 
medical condition or nosographic entity associated with a therapeutic intervention or 
preventive approach. It is therefore considered that the term “marker” is more useful to 
identify patients predisposed to acute deterioration of renal function in this context, due to 
specific pathophysiological features (Toprak, 2007).  
In one third of cases, these markers do not correspond to changeable conditions. Instead, the 
early recognition of remaining situations becomes a prerequisite to the use of prophylactic 
protocols. Even in the absence of incontrovertible evidence, these protocols have shown a 
variable reduction in the incidence of RCI-AKI during prospective or retrospective studies 
(Toprak, 2007) (Fig. 1). 
3.1 Advancing age, chronic nephropathy and accurate assessment of renal function  
Between markers of risk, the reduction in renal function before the administration of 
iodinated contrast medium plays a predominant significance, particularly if baseline 
glomerular filtration rate values are < 60 mL/min/1.73 m2, that is in the course of 
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The decrease of renal function can not be revealed by routine measurement of  serum 
creatinine, because there is an inverse, non-linear relationship between serum creatinine 
(varying with the muscle mass, age and sex of the patient) and corresponding glomerular 
filtration rate. In any case, glomerular filtration rate tends to decrease progressively with 
increasing age and can be measured indirectly by creatinine clearance (Detrenis et al., 
2007b). A recent analysis of more than 20000 patients undergoing coronary angiography 
showed that there is a significantly higher incidence of RCI-AKI in the elderly, especially 
women, who usually have a net reduction of glomerular filtration rate even when there is an 
apparently normal serum creatinine. Indeed, a relative reduction in muscle mass is 
frequently observed in these subjects (Sidhu et al., 2008) (Fig. 2). 
 
Fig. 1. Risk markers for contrast nephropathy 
When the creatinine clearance (1) is not easily achieved trough the urinary output collection, 
so-called MDRD or Levey equation (from the Modification of Diet in Renal Disease Study) 
(2) can be used to estimate glomerular filtration rate (Levey et al., 1999). However, the 
simple evaluation of creatinine clearance by classical Cockcroft and Gault formula (3), which 
consider daily urinary creatinine and only requires knowledge of body weight, age and sex 
of the patient, it is appropriate to clinical practice (Cockcroft & Gault, 1976). 
 urine creatinine  daily urinary outputcreatinine clearance 






(140 - age) x body weight
creatinine clearance  x 0.85 (if female)
serum creatinine  72
=
×
  (2) 
 
( ) 1.154 0.203  
1.154 0.203  
estimated GFR 186  serum creatinine (age) x 0.742 (if female)
                       186  (serum creatinine) (age) x 1.210 (if afro-american) 
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Cystatin C, produced at a constant rate by nucleated cells and released into circulation 
(normal values <0.95 mg/L in subjects aged < 45 years, up to 1.2 mg/L in older), was 
recently identified as a marker of renal injury early and easily measurable. It is freely filtered 
by the glomerulus and completely reabsorbed and metabolized, but not secreted by cells of 
the proximal tubule. Furthermore, it is not subject to significant urinary excretion, and is not 
affected by gender or muscle mass of the patient (Perkins et al., 2005). 
Some studies have used direct measurements of glomerular filtration rate as a gold standard 
to compare the use of cystatin C with serum creatinine and serum creatinine-based 
assessments, demostrating the superiority of the former especially in diabetic patients 
(Perkins et al., 2005). 
The data on clinical use of this method, however, are controversial. The serum 
concentrations of cystatin C identify a condition of preclinical renal damage earlier than 
other laboratory parameters, and are also a possible risk marker for heart failure and other 
cardiovascular events in elderly patients. On the contrary, is not yet clear the real influence 
of other factors (cigarette smoking, thyroid disease, high levels of C-reactive protein, 
corticosteroid therapy) on these measurements (Burkhardt et al., 2002). 
In other words, the accuracy of this diagnostic test has been documented when the 
sensitivity of serum creatinine measurement is reduced. However, cystatin C can be 
interpreted not only as a marker of renal function, but also as generic indicator of 
inflammatory processes (Burkhardt et al., 2002). In addition, quantitative data on extrarenal 
clearance of the molecule are not available. Therefore, because its early serum increase 
(within 24 hours after contrast administration) it could be a useful parameter for RCI-AKI 
after angiographic procedures, but requires further prospective evaluation for large-scale 
use (Detrenis et al., 2007b). 
 
Fig. 2. Serum creatinine, creatinine clearance and age. 1: male, 60 kg, 40 years. 2: female, 60 
kg, 40 years. 3: male, 60 kg, 60 years. 4: male, 60 kg, 80  years. 5: male, 60 kg, 90 years 
www.intechopen.com
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3.2 Impaired fasting glucose, diabetes mellitus and its complications 
Between changes in carbohydrate, lipid and protein profile (dyslipidemia, hyperuricemia, 
metabolic syndrome), diabetes mellitus – according to definition in use, two measurements 
of fasting plasma glucose > 126 mg/dL – does not seem constitute an additional risk for 
RCI-AKI in itself, but only if there is consequent impairment of renal function (Parfrey PS et 
al., 1989). 
Conversely, a prospective evaluation suggests a slight, but significant increase in the 
incidence of RCI-AKI in diabetic, non-nephropatic subjects, and even for those with 
impaired fasting glucose, compared to the general population (Toprak et al., 2007). 
This is consistent with the hypothesis that the so-called endothelial dysfunction contributes 
to development of disease. In fact, it is present in all the above conditions of dysglycemia. At 
the level of the renal glomerulus, it leads to reduced availability of vasodilatory substances, 
such as nitric oxide and prostaglandins, which are synthesized in the endothelium. In this 
way, the renal ischemia associated with administration of iodinated contrast is encouraged, 
through the role of oxygen free radicals, which are able to induce the formation of reactive 
species in enzymes and membrane protein structures, using mechanisms of nitrosylation 
and oxidation (Detrenis et al., 2005). 
3.3 Dehydration and relative hypovolemia 
Even patients with heart failure and low cardiac output leading to reduced renal perfusion 
should be considered at increased risk for RCI-AKI (Thomsen & Morcos, 2003). This 
condition may worsen hypoxia and ischemia of the kidney caused by iodinated contrast 
agents. After an initial vasodilation, contrast media lead to a prolonged vasoconstriction in the 
medulla of the nephron, which already is less perfused than the cortex (Detrenis et al., 2005). 
Subjects with the effective blood volume depletion, peripheral hypoperfusion, hypotension 
can be found under the same conditions. A similar trend is observed during sepsis, liver 
disease with severe hypoalbuminemia and dysproteinaemia, or in severe protein loss from 
any cause (Savazzi et al., 1997). 
Periprocedural hydration and consequent volume expansion of the patient appear as the 
only safe options for RCI-AKI prophylaxis. They stimulate physiological diuresis and dilute 
concentrations of contrast medium and circulating mediators of vasoconstriction (adenosine, 
endothelin, angiotensin II). Therefore, true effectiveness of parenteral infusion protocols 
does not depend on the characteristics of the fluids used, or peculiar infusion rate. The use 
of solutions of sodium bicarbonate (154 mEq/L, 3 mL/kg/hour to 1 hour before the 
procedure, 1 mL/kg/ hour in the next 6 hours) (Merten et al., 2004) or isotonic saline (1 
mL/kg/hour, 12 hours before and 12 hours after the procedure) (Mueller et al., 2002) is 
designed to correct the evident or latent depletion of the extra- and intracellular body 
compartments (Meschi et al., 2006). 
4. Iodinated contrast media and other drugs 
High-osmolal appear to be more nephrotoxic than current low-osmolal contrast media and 
recent iso-osmolal dimers, which did not demonstrate a favorable cost-effectiveness ratio 
(Savazzi et al., 2005; Detrenis et al., 2007c). 
www.intechopen.com
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Although the CM-induced renal damage is dose-dependent, the volume below which the 
risk is reduced has not been identified, particularly when there is a preexisting decrease in 
renal function associated with diabetes (Meschi et al., 2006). 
The intra-arterial route of administration (eg, interventional cardiology) is associated with 
an increased risk of RCI-AKI that the intravenous (eg, computed tomography), especially 
when examinations are repeated in succession at an interval of time less than 72 hours 
(Detrenis et al., 2007a). 
In the case of concomitant use of contrast media, it is mandatory to avoid traditional 
nephrotoxic drugs (eg aminoglycosides), as well as nonsteroidal anti-inflammatory drugs, 
which can reduce the filtrate due to inhibition of intrarenal vasodilatation (Meschi et al., 
2006). 
The continuous treatment with agents that interfere with the renin-angiotensin system 
(angiotensin converting enzyme inhibitors, angiotensin receptor antagonists) contribute to 
the increase in the incidence of RCI-AKI in patients with chronic kidney disease. In fact, they 
cause efferent arteriolar vasodilation and thus the relative reduction of pressure within the 
glomerulus. According to some evidence, angiotensin converting enzyme inhibitors, 
angiotensin receptor blockers and diuretics should be discontinued the day before and day 
of the procedure with contrast, and should be taken after 2 days, unless contraindicated 
(Komenda et al., 2007; Cirit et al., 2006). However, more recent studies refute the efficacy of 
withdrawal (Rosenstock et al., 2008); on the contrary, telmisartan may play a protective role, 
at least in animals (Duan et al., 2009). 
Extreme caution must be observed in the administration of contrast media in patients with 
diabetes treated with metformin. In fact, renal failure caused or worsened by concomitant 
AKI-RCI tends to result in a significant accumulation of biguanide, with possible 
development of lactic acidosis (Thomsen & Morcos, 1999). 
5. The myth of monoclonal gammopathies 
Until a few years ago, many clinicians prescribing the so called "screening for Bence Jones 
proteinuria" before performing an examination with contrast medium (Strada et al., 2008).  
Many laboratories provided (and still provide) a report in mg/dL, compared with a normal 
range (0 – 0.8 mg/dL). With this system, “Bence Jones proteinuria” greater than 0.8 mg/dL 
was defined as positive. 
Many criticisms can be conducted in this model. Under normal conditions, immunoglobulin 
light chains (kappa, lambda) are freely filtered by the glomerulus and subsequently 
reabsorbed from the tubule to 99%. A normal urinary excretion of light chains is estimated 
at 20-40 mg per day (Strada et al., 2008). This amount increases significantly in case of 
impaired tubular reabsorption, for example during tubule-interstitial nephropathy, but 
concerns polyclonal light chains that are not of neoplastic origin.  
On the contrary, the real Bence Jones protein was first described in 1962 as "consisting of 
monoclonal light chains" and produced by a single clone of B lymphocytes. It appears in the 
urine when the efficiency of tubular reabsorption is saturated, as in the course of diseases 
such as multiple myeloma, Waldenstrom's macroglobulinemia and lymphoproliferative 
www.intechopen.com
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disorders (Strada et al., 2008).   For this reason, a pathological parameter (M monoclonal 
component), which under normal conditions should not be detected, can not be expressed in 
a range defined as physiological (0 – 0.8 mg/dL). 
Moreover, despite the monoclonal gammopathies have been reported as risk markers for 
RCI-AKI for a long time, all the reviews of the scientific literature indicate that the 
association between the two comorbidities occurs only if a severe depletion of water and 
blood volume of the patient is demonstrated, or when the hematological malignancy has led 
to renal failure or hypercalcemic syndrome. 
Thus, the monoclonal gammopathies should not be considered as primary contributing 
factors of the RCI-AKI, and screening of the so-called Bence Jones proteinuria has no clinical 
significance in patients undergoing contrast media (Meschi et al., 2006; Toprak, 2007). The 
presence of monoclonal gammopathy should be considered critically and the procedure 
with contrast medium, when necessary, can be implemented after evaluating volume, fluid 
and electrolyte status and renal function of the patient (Fig. 3). 
 
Fig. 3. Management of the patient undergoing contrast medium examination. 
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